Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.685
Filter
1.
PLoS One ; 19(6): e0304605, 2024.
Article in English | MEDLINE | ID: mdl-38861499

ABSTRACT

Canine Alopecia X is a non-inflammatory hair loss disorder of unknown etiology that predominantly affects German Spitz dogs. Treatment modalities include hormone and/or melatonin supplementation and low trauma microneedling. Melatonin influences hair growth and pigmentation in several species and presents a low risk of adverse effects when used in dogs with Alopecia X. Photobiomodulation (PBM) is frequently used in human androgenetic alopecia and alopecia areata; despite this, PBM remains unexplored in canine Alopecia X. To address this knowledge gap, sixty dogs of both sexes will be randomly assigned to three groups: (i) melatonin only group (3 mg/Kg, n = 20); (ii) PBM only group (diode laser, wavelength 660nm, 100mw power, with 3 J/point, 2 sessions/week for 3 months, n = 20); (ii) PBM + melatonin group (n = 20). The objective is to determine the potential of PBM alone or in conjunction with melatonin supplementation in promoting hair regrowth (hair density and diameter) by means of dermatoscopy and planimetry over a period of 90 days.


Subject(s)
Alopecia , Low-Level Light Therapy , Melatonin , Animals , Melatonin/therapeutic use , Melatonin/pharmacology , Dogs , Low-Level Light Therapy/methods , Alopecia/drug therapy , Alopecia/radiotherapy , Alopecia/veterinary , Male , Female , Double-Blind Method , Dog Diseases/radiotherapy , Hair/growth & development , Hair/drug effects
2.
Ulus Travma Acil Cerrahi Derg ; 30(6): 397-405, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38863293

ABSTRACT

BACKGROUND: Wound healing involves the repair of skin and other soft tissues after an injury. Royal jelly, a product of bees, possesses antioxidant, anti-inflammatory, antibacterial, and antiviral properties. Melatonin, a circadian indoleamine, is produced in the pineal gland and other organs. This study explores the effects of melatonin and royal jelly, both individually and combined, on wound healing in geriatric and young mice. METHODS: The study includes 90 Balb/C mice divided into ten groups to assess the effects of royal jelly and melatonin on wound healing. Royal jelly was applied topically at a concentration of 300 mg/kg. Melatonin was formulated in a vaseline-based pomade at a concentration of 5 mg/kg. The substances were applied either separately or in combination to wounds created on the mice. RESULTS: Both substances significantly enhanced wound healing at a macroscopic level in both age groups. Melatonin was found to be more effective during the initial wound formation process, whereas royal jelly was more beneficial during the granulation phase. However, significant results at a histopathological level were observed only in geriatric animals. CONCLUSION: The findings suggest a potential new therapeutic approach to enhance wound healing, particularly in elderly individuals. However, these findings need to be supported through further research and clinical trials.


Subject(s)
Fatty Acids , Melatonin , Mice, Inbred BALB C , Wound Healing , Animals , Melatonin/pharmacology , Melatonin/administration & dosage , Melatonin/therapeutic use , Wound Healing/drug effects , Mice , Fatty Acids/administration & dosage , Male , Disease Models, Animal , Antioxidants/pharmacology , Antioxidants/administration & dosage , Wounds and Injuries/drug therapy , Wounds and Injuries/pathology
4.
Minerva Anestesiol ; 90(6): 509-519, 2024 06.
Article in English | MEDLINE | ID: mdl-38869264

ABSTRACT

BACKGROUND: The current study was designed to evaluate the role of prophylactic melatonin administration in reducing delirium occurrence in elderly patients undergoing colorectal cancer surgeries. METHODS: One hundred patients of both genders undergoing elective colorectal cancer surgeries under general anesthesia were randomly allocated into two equal groups. A treatment group of patients (Melatonin group) received five mg of melatonin the night before surgery, twelve hours before the scheduled surgery time, and an additional five mg of melatonin two hours before surgery. The control group of patients received placebo tablets at the same time points. Delirium score, sedation score, pain score, hemodynamics, oxygen saturation, and blood requirements were recorded. RESULTS: Twenty-eight patients (56%) in the control group versus 18 (36%) in the melatonin group developed delirium (P=0.045), OR=2.26, 95% CI: 1.013-5.05. Five patients (18%) in the control group versus six (33%) in the melatonin group developed delirium on discharge from the recovery room (P=0.749), OR=1.22, 95% CI: 0.34-4.31, while 23 patients (82%) in the control group versus 12 (66%) in the melatonin group developed delirium six hours postoperative (P=0.021), OR=1.705, 95% CI: 1.02-2.81 with higher nursing delirium screening score in the control group 2 (1, 4) versus 1 (0, 2) in the melatonin group (P=0.002), 95% CI: 1.77-2.71. CONCLUSIONS: The prophylactic administration of melatonin may decrease the incidence of postoperative delirium in elderly patients undergoing colorectal surgeries under general anesthesia.


Subject(s)
Delirium , Melatonin , Postoperative Complications , Humans , Melatonin/therapeutic use , Male , Female , Aged , Postoperative Complications/prevention & control , Delirium/prevention & control , Double-Blind Method , Colorectal Neoplasms/surgery , Aged, 80 and over , Emergence Delirium/prevention & control
5.
Expert Rev Neurother ; 24(6): 585-596, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38738544

ABSTRACT

INTRODUCTION: Sleep disorders represent an important comorbidity in individuals with ADHD. While the links between ADHD and sleep disturbances have been extensively investigated, research on the management of sleep disorders in individuals with ADHD is relatively limited, albeit expanding. AREAS COVERED: The authors searched PubMed, Medline, PsycInfo, Embase+Embase Classic, Web of Sciences databases, and clinicaltrials.gov up to 4 January 2024, for randomized controlled trials (RCTs) of any intervention for sleep disorders associated with ADHD. They retained 16 RCTs (eight on pharmacological and eight on non-pharmacological interventions), supporting behavioral intervention and melatonin, and nine ongoing RCTs registered on clinicaltrials.gov. EXPERT OPINION: The pool of RCTs testing interventions for sleep disorders in individuals with ADHD is expanding. However, to inform clinical guidelines, there is a need for additional research in several areas, including 1) RCTs based on a precise phenotyping of sleep disorders; 2) pragmatic RCTs recruiting neurodevelopmental populations representative of those seen in clinical services; 3) trials testing alternative interventions (e.g. suvorexant or light therapy) or ways to deliver them (e.g. online); 4) sequential and longer-term RCTs; 5) studies testing the impact of sleep interventions on outcomes other than sleep; 6) and implementation of advanced evidence synthesis and precision medicine approaches.


Subject(s)
Attention Deficit Disorder with Hyperactivity , Sleep Wake Disorders , Humans , Attention Deficit Disorder with Hyperactivity/therapy , Attention Deficit Disorder with Hyperactivity/complications , Child , Sleep Wake Disorders/therapy , Randomized Controlled Trials as Topic , Melatonin/therapeutic use , Behavior Therapy
6.
Eur J Pharmacol ; 975: 176646, 2024 Jul 15.
Article in English | MEDLINE | ID: mdl-38762157

ABSTRACT

Severe acute pancreatitis (SAP) is a complicated inflammatory reaction that impacts the pancreas, often resulting in damage to numerous organs. This disorder encompasses a range of processes such as inflammation, oxidative stress, and pancreatitis. The hormone melatonin (MT) is primarily secreted by the pineal gland and plays a crucial role in mitigating inflammation, countering the harmful effects of free radicals, and regulating oxidative stress. The aim of this research was to investigate the potential protective impact and the underlying mechanism of melatonin in mice afflicted with SAP. The biochemical and histological assessments unequivocally demonstrated that melatonin effectively inhibited necrosis, infiltration, edema and cell death in pancreatic tissues, thereby suppressing acute pancreatitis. Notably, melatonin also alleviated the consequent harm to distant organs, notably the lungs, liver, and kidneys. Furthermore, both preventive and therapeutic administration of melatonin prompted nuclear factor E2-related factor 2 (Nrf2) activation followed by Nrf2 target gene expression. Nrf2 initiates the activation of antioxidant genes, thereby providing defense against oxidative stress. Conversely, Nrf2 reduction may contribute to impaired antioxidant protection in SAP. The beneficial impact of Nrf2 on antioxidants was absent in Nrf2-knockout mice, leading to the accumulation of LDH and exacerbation of cell death. This deterioration in both pancreatitis and injuries in distant organs intensified significantly. The results indicate that melatonin has an enhanced ability to protect against multiorgan damage caused by SAP, which is accomplished through the increase in Nrf2 expression. Additionally, Nrf2 initiates the activation of antioxidant genes that offer defense against cell death.


Subject(s)
Melatonin , NF-E2-Related Factor 2 , Oxidative Stress , Pancreatitis , Signal Transduction , Animals , NF-E2-Related Factor 2/metabolism , NF-E2-Related Factor 2/genetics , Melatonin/pharmacology , Melatonin/therapeutic use , Signal Transduction/drug effects , Pancreatitis/drug therapy , Pancreatitis/pathology , Pancreatitis/metabolism , Mice , Oxidative Stress/drug effects , Male , Antioxidants/pharmacology , Antioxidants/therapeutic use , Mice, Knockout , Pancreas/drug effects , Pancreas/pathology , Pancreas/metabolism , Mice, Inbred C57BL , Acute Disease
7.
Int J Mol Sci ; 25(9)2024 Apr 29.
Article in English | MEDLINE | ID: mdl-38732075

ABSTRACT

Melatonin and sericin exhibit antioxidant properties and may be useful in topical wound healing patches by maintaining redox balance, cell integrity, and regulating the inflammatory response. In human skin, melatonin suppresses damage caused by ultraviolet radiation (UVR) which involves numerous mechanisms associated with reactive oxygen species/reactive nitrogen species (ROS/RNS) generation and enhancing apoptosis. Sericin is a protein mainly composed of glycine, serine, aspartic acid, and threonine amino acids removed from the silkworm cocoon (particularly Bombyx mori and other species). It is of interest because of its biodegradability, anti-oxidative, and anti-bacterial properties. Sericin inhibits tyrosinase activity and promotes cell proliferation that can be supportive and useful in melanoma treatment. In recent years, wound healing patches containing sericin and melatonin individually have attracted significant attention by the scientific community. In this review, we summarize the state of innovation of such patches during 2021-2023. To date, melatonin/sericin-polymer patches for application in post-operational wound healing treatment has been only sparingly investigated and it is an imperative to consider these materials as a promising approach targeting for skin tissue engineering or regenerative dermatology.


Subject(s)
Melanoma , Melatonin , Sericins , Wound Healing , Melatonin/therapeutic use , Melatonin/pharmacology , Humans , Wound Healing/drug effects , Melanoma/drug therapy , Melanoma/metabolism , Melanoma/pathology , Animals , Sericins/pharmacology , Sericins/therapeutic use , Antioxidants/therapeutic use , Antioxidants/pharmacology , Skin Neoplasms/drug therapy , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
8.
Minerva Med ; 115(2): 125-142, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38713204

ABSTRACT

INTRODUCTION: Melatonin, a hormone produced by the pineal gland, regulates the sleep-wake cycle and is effective in restoring biological rhythms. Prolonged-release melatonin (PRM) is designed to mimic the natural physiological pattern of melatonin release. In circadian medicine, PRM can be used to treat sleep and circadian rhythm disorders, as well as numerous organic diseases associated with sleep disorders. EVIDENCE ACQUISITION: This systematic review analyzed 62 studies and adhered to the PRISMA guidelines, examining the effectiveness of PRM in organic pathologies and mental disorders. EVIDENCE SYNTHESIS: The main evidence concerns primary insomnia in subjects over the age of 55, showing significant improvements in sleep quality. In neurodevelopmental disorders, there is evidence of a positive impact on sleep quality and quality of life for patients and their caregivers. PRM shows efficacy in the treatment of sleep disorders in mood disorders, schizophrenia, and neurocognitive disorders, but requires further confirmation. The additional use of PRM is supported for the withdrawal of chronic benzodiazepine therapies. The tolerability and safety of PRM are excellent, with ample evidence supporting the absence of tolerance and dependence. CONCLUSIONS: Overall, PRM in circadian medicine is an effective chronopharmaceutical for restoring the sleep-wake rhythm in patients with insomnia disorder. This efficacy may also extend to sleep disorders associated with mood, neurodevelopmental and neurocognitive disorders, suggesting a further potential role in insomnia associated with various organic diseases.


Subject(s)
Delayed-Action Preparations , Melatonin , Sleep Initiation and Maintenance Disorders , Melatonin/therapeutic use , Melatonin/administration & dosage , Humans , Sleep Initiation and Maintenance Disorders/drug therapy , Circadian Rhythm/physiology , Sleep Disorders, Circadian Rhythm/drug therapy , Neurodevelopmental Disorders/drug therapy , Mood Disorders/drug therapy , Sleep Wake Disorders/drug therapy , Sleep Wake Disorders/etiology , Sleep Quality , Neurocognitive Disorders/drug therapy , Neurocognitive Disorders/etiology
9.
Sleep Med ; 119: 511-517, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38805858

ABSTRACT

The present article explores the connection between insomnia and Autism Spectrum Disorder (ASD), focusing on the efficacy and safety of melatonin treatments as supported by existing research and current guidelines. In this narrative review a group of Italian experts provide an analysis of the various aspects of managing insomnia in children with ASD, highlighting key points that could enhance the quality of life for both patients and their caregivers. This includes the significance of comprehensively understanding the root causes of a child's sleep difficulties for more effective, long-term management. Insomnia, a condition frequently documented in neurodevelopmental disorders such as ASD, greatly affects the lives of patients and caregivers. Recent data show that melatonin-based formulations are effective and safe for treating ASD-related insomnia both short and long term. In particular, prolonged-release melatonin is poised to be the optimal choice for this patient population. This formulation is approved for the treatment of insomnia in children and adolescents aged 2-18 years suffering from ASD and/or Smith-Magenis syndrome, where sleep hygiene measures and behavioral treatments have not been sufficient. In support, emerging research in pediatric settings indicates long-term efficacy and safety, although further research efforts are still needed. Current guidelines recommend managing insomnia and sleep disturbances in ASD using a combination of behavioral and pharmacological methods, primarily melatonin. Recent concerns about accidental melatonin ingestion highlight the need for high purity standards, such as pharmaceutical-grade prolonged-release formulations. The article also summarizes emerging molecular mechanisms from preclinical research, suggesting future therapeutic approaches.


Subject(s)
Autism Spectrum Disorder , Melatonin , Sleep Initiation and Maintenance Disorders , Humans , Melatonin/therapeutic use , Sleep Initiation and Maintenance Disorders/drug therapy , Autism Spectrum Disorder/drug therapy , Autism Spectrum Disorder/complications , Child , Adolescent , Quality of Life
10.
Sleep Med ; 119: 222-228, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38704869

ABSTRACT

Though it is widely prescribed for improving sleep of children with autism and other neurogenetic disorders, there is a need for practical guidance to clinicians on the use of melatonin for managing insomnia in this population. Because data were either lacking or inconclusive, a task force was established by the International Pediatric Sleep Association (IPSA) to examine the literature based on clinical trials from 2012 onwards. A summary of evidence pertaining to melatonin's utility and potential side effects, practice-related caveats, and insights for use are published herewith.


Subject(s)
Melatonin , Sleep Initiation and Maintenance Disorders , Humans , Melatonin/therapeutic use , Sleep Initiation and Maintenance Disorders/drug therapy , Child , Autistic Disorder/drug therapy , Autistic Disorder/complications
11.
Cells ; 13(10)2024 May 18.
Article in English | MEDLINE | ID: mdl-38786094

ABSTRACT

Post-stroke cognitive impairment (PSCI) remains the most common consequence of ischemic stroke. In this study, we aimed to investigate the role and mechanisms of melatonin (MT) in improving cognitive dysfunction in stroke mice. We used CoCl2-induced hypoxia-injured SH-SY5Y cells as a cellular model of stroke and photothrombotic-induced ischemic stroke mice as an animal model. We found that the stroke-induced upregulation of mitophagy, apoptosis, and neuronal synaptic plasticity was impaired both in vivo and in vitro. The results of the novel object recognition test and Y-maze showed significant cognitive deficits in the stroke mice, and Nissl staining showed a loss of neurons in the stroke mice. In contrast, MT inhibited excessive mitophagy both in vivo and in vitro and decreased the levels of mitophagy proteins PINK1 and Parkin, and immunofluorescence staining showed reduced co-localization of Tom20 and LC3. A significant inhibition of mitophagy levels could be directly observed under transmission electron microscopy. Furthermore, behavioral experiments and Nissl staining showed that MT ameliorated cognitive deficits and reduced neuronal loss in mice following a stroke. Our results demonstrated that MT inhibits excessive mitophagy and improves PSCI. These findings highlight the potential of MT as a preventive drug for PSCI, offering promising therapeutic implications.


Subject(s)
Cognitive Dysfunction , Melatonin , Mitophagy , Stroke , Animals , Melatonin/pharmacology , Melatonin/therapeutic use , Mitophagy/drug effects , Cognitive Dysfunction/drug therapy , Cognitive Dysfunction/pathology , Cognitive Dysfunction/etiology , Mice , Stroke/complications , Stroke/drug therapy , Stroke/pathology , Male , Humans , Disease Models, Animal , Mice, Inbred C57BL , Apoptosis/drug effects , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , Neuronal Plasticity/drug effects , Cell Line, Tumor , Protein Kinases , Ubiquitin-Protein Ligases
12.
Int J Mol Sci ; 25(10)2024 May 08.
Article in English | MEDLINE | ID: mdl-38791160

ABSTRACT

While primarily produced in the pineal gland, melatonin's influence goes beyond its well-known role in regulating sleep, nighttime metabolism, and circadian rhythms, in the field of chronobiology. A plethora of new data demonstrates melatonin to be a very powerful molecule, being a potent ROS/RNS scavenger with anti-inflammatory, immunoregulatory, and oncostatic properties. Melatonin and its metabolites exert multiple beneficial effects in cutaneous and systemic aging. This review is focused on the neuroprotective role of melatonin during aging. Melatonin has an anti-aging capacity, retarding the rate of healthy brain aging and the development of age-related neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, etc. Melatonin, as well as its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), can reduce oxidative brain damage by shielding mitochondria from dysfunction during the aging process. Melatonin could also be implicated in the treatment of neurodegenerative conditions, by modifying their characteristic low-grade neuroinflammation. It can either prevent the initiation of inflammatory responses or attenuate the ongoing inflammation. Drawing on the current knowledge, this review discusses the potential benefits of melatonin supplementation in preventing and managing cognitive impairment and neurodegenerative diseases.


Subject(s)
Aging , Brain , Melatonin , Neurodegenerative Diseases , Neuroprotection , Neuroprotective Agents , Melatonin/metabolism , Melatonin/pharmacology , Melatonin/therapeutic use , Humans , Brain/metabolism , Brain/drug effects , Aging/metabolism , Aging/drug effects , Animals , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/drug therapy , Neuroprotection/drug effects , Neuroprotective Agents/therapeutic use , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Kynuramine/metabolism , Kynuramine/analogs & derivatives
13.
Int J Mol Sci ; 25(10)2024 May 09.
Article in English | MEDLINE | ID: mdl-38791203

ABSTRACT

Melatonin is ubiquitously present in all animals and plants, where it exerts a variety of physiological activities thanks to its antioxidant properties and its key role as the first messenger of extracellular signaling functions. Most of the clinical studies on melatonin refer to its widespread oral use as a dietary supplement to improve sleep. A far smaller number of articles describe the clinical applications of topical melatonin to treat or prevent skin disorders by exploiting its antioxidant and anti-inflammatory activities. This review focuses on the clinical studies in which melatonin was applied on the skin as a photoprotective, anti-aging, or hair growth-promoting agent. The methodologies and results of such studies are discussed to provide an overall picture of the state of the art in this intriguing field of research. The clinical studies in which melatonin was applied on the skin before exposure to radiation (UV, sunlight, and high-energy beams) were all characterized by an appropriate design (randomized, double-blind, and placebo-controlled) and strongly support its clinical efficacy in preventing or reducing skin damage such as dermatitis, erythema, and sunburn. Most of the studies examined in this review do not provide a clear demonstration of the efficacy of topical melatonin as a skin anti-aging or as a hair growth-promoting agent owing to limitations in their design and/or to the use of melatonin combined with extra active ingredients, except for one trial that suggests a possible beneficial role of melatonin in treating some forms of alopecia in women. Further research efforts are required to reach definitive conclusions concerning the actual benefits of topical melatonin to counteract skin aging and hair loss.


Subject(s)
Administration, Topical , Melatonin , Melatonin/pharmacology , Melatonin/administration & dosage , Melatonin/therapeutic use , Humans , Antioxidants/pharmacology , Antioxidants/administration & dosage , Antioxidants/therapeutic use , Animals , Skin Aging/drug effects , Clinical Studies as Topic , Skin/drug effects , Skin/metabolism , Skin Diseases/drug therapy
14.
J Int Med Res ; 52(5): 3000605241239854, 2024 May.
Article in English | MEDLINE | ID: mdl-38735057

ABSTRACT

OBJECTIVE: To assess the efficacy and safety of perioperative melatonin and melatonin agonists in preventing postoperative delirium (POD). METHODS: We conducted a systematic search for randomized controlled trials (RCTs) published through December 2022. The primary outcome was efficacy based on the incidence of POD (POD-I). Secondary outcomes included efficacy and safety according to the length of hospital or intensive care unit stay, in-hospital mortality, and adverse events. Subgroup analyses of POD-I were based on the type and dose of drug (low- and high-dose melatonin, ramelteon), the postoperative period (early or late), and the type of surgery. RESULTS: In the analysis (16 RCTs, 1981 patients), POD-I was lower in the treatment group than in the control group (risk ratio [RR] = 0.57). POD-I was lower in the high-dose melatonin group than in the control group (RR = 0.41), whereas no benefit was observed in the low-dose melatonin and ramelteon groups. POD-I was lower in the melatonin group in the early postoperative period (RR = 0.35) and in patients undergoing cardiopulmonary surgery (RR = 0.54). CONCLUSION: Perioperative melatonin or melatonin agonist treatment suppressed POD without severe adverse events, particularly at higher doses, during the early postoperative period, and after cardiopulmonary surgery.


Subject(s)
Delirium , Melatonin , Postoperative Complications , Melatonin/therapeutic use , Melatonin/administration & dosage , Melatonin/adverse effects , Humans , Postoperative Complications/prevention & control , Postoperative Complications/drug therapy , Delirium/prevention & control , Delirium/drug therapy , Perioperative Care/methods , Indenes/therapeutic use , Indenes/adverse effects , Indenes/administration & dosage , Randomized Controlled Trials as Topic , Length of Stay , Treatment Outcome , Hospital Mortality
17.
JAMA Netw Open ; 7(5): e2412502, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38776087

ABSTRACT

This cohort study examines patterns of melatonin use among participants in the Adolescent Brain Cognitive Development (ABCD) Study and characterizes factors associated with use.


Subject(s)
Melatonin , Humans , Melatonin/therapeutic use , Child , Female , Male , Child, Preschool , Adolescent , United States , Cross-Sectional Studies , Infant
18.
Iran J Med Sci ; 49(5): 313-321, 2024 May.
Article in English | MEDLINE | ID: mdl-38751874

ABSTRACT

Background: There is no definite recommendation for melatonin supplementation in episodic migraine. This study aimed to evaluate the effect of melatonin on reducing the frequency and severity of migraine attacks. Methods: This randomized, double-blind clinical trial was conducted at Golestan Hospital of Ahvaz, Iran, in 2021. A total of 60 patients with episodic migraine were randomly assigned into 2 groups of receiving 3 mg melatonin (intervention group; n=30) or the same dose of placebo (control group; n=30) along with baseline therapy (propranolol 20 mg, BID) for two months. The attack frequency, attack duration, attack severity (based on VAS), the number of analgesic intakes, drug complications, Migraine Disability Assessment score (MIDAS), and Pittsburgh sleep quality index (PSQI) were evaluated at baseline and in the first, second, third, and fourth months of follow-up. The independent t test, chi-square, and analysis of variance (ANOVA) with repeated measures were used to compare variables between the two groups. Results: In both groups, the frequency, duration, and severity of attacks, taking analgesics, MIDAS, and PSQI scores during follow-up decreased significantly (P<0.001). After treatment, the mean frequency (P=0.032) and duration of attacks (P=0.001), taking analgesic (P<0.001), and MIDAS (P<0.001) and PSQI scores (P<0.001) in the melatonin group were lower than placebo. Only the attack severity was not significantly different between the two groups (P=0.126). Side effects were observed in two patients (6.7%) in the melatonin group and one patient (3.3%) in the placebo group (P>0.999). Conclusion: Our study shows that melatonin was more efficacious than the placebo in the reduction of frequency and duration of migraine attacks. It was equally safe as the placebo and might be effective in the preventive treatment of episodic migraine in adults.Trial Registration Number: IRCT20190107042264N5.


Subject(s)
Melatonin , Migraine Disorders , Humans , Melatonin/therapeutic use , Melatonin/pharmacology , Migraine Disorders/drug therapy , Double-Blind Method , Male , Female , Adult , Middle Aged , Iran , Severity of Illness Index , Treatment Outcome , Analgesics/therapeutic use , Analgesics/pharmacology
19.
Integr Cancer Ther ; 23: 15347354241237520, 2024.
Article in English | MEDLINE | ID: mdl-38622853

ABSTRACT

INTRODUCTION: Although breast cancer is common worldwide, if diagnosed early and treated on time, the probability of recovery is high and patients often experience a long life. Reducing the quality of life is a common side effect in patients. Melatonin may have an important role in fatigue, sleep disorders and, as a result, the health-related quality of life (HRQoL) in people. About 184 patients with breast cancer were enrolled in 2 groups: intervention with daily melatonin intake of 18 mg for 3 years (93 patients) and the control group with placebo intake (91 patients). Health-related quality of life and the effect of melatonin on increasing that were evaluated with the EORTC QLQ-C30 questionnaire, third edition at the beginning, 2 months later and 3 years after the beginning of the study. RESULTS: The general score of the HRQoL was significantly different both in the passage of time and in the comparative study of the 2 groups, and it was better in the melatonin group (P < .05). CONCLUSION: Long-term use of 18 mg of melatonin for 3 years in patients with non-metastatic breast cancer can lead to an increase in the patients' quality of life.


Subject(s)
Breast Neoplasms , Melatonin , Humans , Female , Quality of Life , Breast Neoplasms/therapy , Melatonin/therapeutic use , Follow-Up Studies , Surveys and Questionnaires
20.
J Craniomaxillofac Surg ; 52(6): 786-791, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38609755

ABSTRACT

Posttraumatic and postsurgical sensory disturbance is a known complication of almost all zygomaticomaxillary (ZMC) complex fractures involving the infraorbital nerve, for which few treatments are effective. Our study used neurosensory assessments to evaluate the efficacy of melatonin on pain and nerve healing following ZMC surgery. Sixty-four randomly allocated ZMC fracture patients were prophylactically administered either oral melatonin or an identical placebo for 15 consecutive days. Pre- and postsurgical clinical parameters included subjective pain, numbness, and objective neurosensory function. Melatonin significantly reduced subjective pain perception in the early postoperative days, with a significant difference in VAS scores between the groups from postoperative day 3 (p = 0.048) until day 7 (p = 0.002). The VAS assessment of subjective numbness perception showed significantly lower self-perceived neurosensory disturbance for patients in the interventional group from the first month (p = 0.039) until the third month (p = 0.005). Objective neurosensory assessment using the pinprick test and two-point discrimination showed statistically significant improvement to almost normal sensation by the first month (p = 0.014) to fully normal sensation by the third month (p = 0.001). The study findings suggest that the prophylactic administration of melatonin confers significant clinical benefits in terms of reduced postoperative pain and improved sensory recovery.


Subject(s)
Maxillary Fractures , Melatonin , Pain, Postoperative , Zygomatic Fractures , Humans , Melatonin/therapeutic use , Zygomatic Fractures/surgery , Pain, Postoperative/prevention & control , Pain, Postoperative/drug therapy , Male , Female , Adult , Maxillary Fractures/surgery , Middle Aged , Pain Measurement , Young Adult , Double-Blind Method , Hypesthesia/etiology , Recovery of Function/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...